HR 32
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-05-01
No summary is available yet.
No bill text is available yet.
|
Date
|
Status
|
|---|---|
| May 9, 2019 | Read. Adopted. |
| May 6, 2019 | From committee: Be adopted. To Consent Calendar. (Ayes 12. Noes 0.) (May 6). |
| May 2, 2019 | Referred to Com. on RLS. |
| May 1, 2019 | Introduced. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| May 9, 2019 | HR 32 Mullin Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| May 6, 2019 | Be adopted. To Consent Calendar. | Assembly Standing Committee on Rules |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
* Testimony in a hearing
** Position recorded in bill analysis
*** Position recorded in written testimony
No support or opposition from interest groups has been recorded yet.
* Testimony in a hearing
** Position recorded in bill analysis
*** Position recorded in written testimony
Date of Hearing: May 6, 2019
ASSEMBLY COMMITTEE ON RULES
Ken Cooley, Chair
ABPCA Bill Id:HR 32 (
Author:Mullin) – As Introduced Ver:May 1, 2019
SUBJECT: Tardive Dyskinesia Awareness Week.
SUMMARY: Proclaims the week of May 6, 2019, as Tardive Dyskinesia Awareness Week to raise awareness of this potentially debilitating disease. Specifically, this resolution makes the following legislative findings:
- Many people with serious, chronic mental illness, bipolar disorder, or severe depression, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics. While ongoing treatment with these medications can be very helpful, and even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD).
- TD is a movement disorder that is characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities. In some cases, people may experience movement of the arms, legs, fingers, and toes. In some cases, it may affect the tongue, lips, and jaw. In other cases, symptoms may include swaying movements of the trunk or hips and may impact the muscles associated with walking, speech, eating, and breathing.
- TD can develop months, years, or decades after a person starts taking DRBAs, and even after they have discontinued use of those medications. Not everyone who takes a DRBA develops TD, but if it develops it is often permanent.
- Common risk factors for TD include advanced age and alcoholism or other substance abuse disorders. Postmenopausal women and people with a mood disorder or a family history of mood disorders are also at higher risk of developing TD.
- A person is at higher risk for TD after taking DRBAs for three months or longer, and studies suggest that the overall risk of developing TD following prolonged exposure to DRBAs is between 10 and 30 percent.
- Years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for TD approved by the United States Food and Drug Administration. TD is often unrecognized and patients suffering from the illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA medications is recommended by the American Psychiatric Association (APA).
- Patients who take DRBAs should be regularly evaluated by their health care providers to ensure that any signs of TD are recognized. Health care providers should use a rating scale recommended by the APA.
FISCAL EFFECT: None
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: Michael Erke / RLS. / (916) 319-2800
Bill Author
Bill Co-Author(s):